- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01003847
Differential Metabolic Effects of Fenofibrate and Fatty Acid
May 9, 2011 updated by: Gachon University Gil Medical Center
The investigators hypothesize that fenofibrate and fatty acid may have different metabolic effects in hypertriglyceridemic patients
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Incheon, Korea, Republic of, 405-760
- Gil Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
23 years to 73 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- hypertriglyceridemia
Exclusion Criteria:
- Overt liver disease Chronic renal failure Hypothyroidism Myopathy Uncontrolled diabetes Severe hypertension
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Placebo
|
fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
|
Active Comparator: fenofibrate
|
fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
|
Active Comparator: fatty acid
drug
|
fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
flow-mediated dilation
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
insulin resistance
Time Frame: 8 weeks of treatment
|
8 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
September 1, 2010
Study Completion (Actual)
September 1, 2010
Study Registration Dates
First Submitted
October 28, 2009
First Submitted That Met QC Criteria
October 28, 2009
First Posted (Estimate)
October 29, 2009
Study Record Updates
Last Update Posted (Estimate)
May 10, 2011
Last Update Submitted That Met QC Criteria
May 9, 2011
Last Verified
October 1, 2010
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GMC-200911
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertriglyceridemia
-
Arrowhead PharmaceuticalsNot yet recruitingSevere Hypertriglyceridemia
-
89bio, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Bulgaria, Canada, Latvia, Spain, Austria, Belgium, Czechia, Georgia, Hungary, Poland, Puerto Rico, Argentina, Chile, France, Germany, United Kingdom
-
Ionis Pharmaceuticals, Inc.RecruitingSevere HypertriglyceridemiaUnited States, Germany, Israel, Spain, Netherlands, Australia, Hungary, Sweden, Denmark, Canada, France, Italy, Turkey, Finland, Bulgaria, Czechia, New Zealand, Norway, Poland, Portugal, Slovakia, South Africa, United Kingdom
-
Sancilio and Company, Inc.WithdrawnSevere Hypertriglyceridemia
-
Arrowhead PharmaceuticalsCompletedSevere HypertriglyceridemiaUnited States, Netherlands, Australia, Canada, New Zealand, Poland, Hungary, Germany
-
AstraZenecaCompletedSevere HypertriglyceridemiaUnited States, Hungary, India, Russian Federation, Denmark, Ukraine, Netherlands
-
AstraZenecaRadiant ResearchCompletedSevere HypertriglyceridemiaUnited States
-
Trygg Pharma, Inc.UnknownSevere HypertriglyceridemiaUnited States
-
National Taiwan University HospitalUnknownHypertriglyceridemia During PregnancyTaiwan
-
DongKoo Bio & PharmaUnknownHyperlipidemia, HypertriglyceridemiaKorea, Republic of
Clinical Trials on fenofibrate, fatty acid, placebo
-
Ohio State University Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast Neoplasms | ArthralgiaUnited States
-
Thammasat UniversityRecruitingPostoperative Pain | Postoperative InflammationThailand
-
University of East AngliaUniversity of Illinois at Chicago; Swinburne University of TechnologyUnknownMild Cognitive Impairment | Subjective Memory ImpairmentUnited Kingdom, United States, Australia
-
University of PennsylvaniaUniversity of Arizona; National Center for Advancing Translational Sciences... and other collaboratorsCompleted
-
Bangabandhu Sheikh Mujib Medical University, Dhaka...Recruiting
-
Cedars-Sinai Medical CenterNational Institute of Mental Health (NIMH); Massachusetts General HospitalCompleted
-
Unilever R&DUMC UtrechtCompletedHealthy | Attention Deficit Hyperactivity DisorderNetherlands
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Cedars-Sinai Medical CenterCompletedMajor Depressive DisorderUnited States
-
Retina Foundation of the SouthwestDSM Nutritional Products, Inc.CompletedInfant DevelopmentUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States